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Abstract 
It is well-known that the human myocardium has a low capacity for self-regeneration. 
This fact is especially important after acute myocardial infarction with subsequent heart 
failure and adverse tissue remodeling. New potential strategies have recently emerged 
for treating heart diseases, such as the possibility of generating large quantities of 
cardiomyocytes through genetic iPSC reprogramming, transdifferentiation for in vitro 
disease modeling, in vivo therapies or telomerase gene reactivation. Approaches based 
on these techniques may represent the new horizon in cardiology with an appropriate 
180-degree turn perspective.  
 
Keywords: acute myocardial infarction; heart failure; remodeling; iPSCs; miRNA; 
telomerase; regenerative medicine. 
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 Acute myocardial infarction (AMI) impairs the regenerative capacity of a tissue, 
the myocardium, with a low capacity for self-regeneration (Boengler et al., 2009). No 
major treatment advances have been made in this area and mortality rates within 1 year 
post-AMI remain high, prompting a need to explore novel cardiac regeneration 
strategies that might also benefit other heart disorders. 
 Several in vivo animal models, mostly with mice, have been developed to unveil 
the biological mechanisms underlying cardiac diseases and to assess regenerative 
strategies, notably gene therapy (Mauritz et al., 2011). A recent study indicated that 
telomerase gene reactivation delivered to adult mice hearts after AMI elongated 
myocardial telomeres, attenuated cardiac remodeling and increased survival rates 
(+17%) compared with non-treated controls (Bar et al., 2014). The authors suggested 
that telomerase activation could be used to regenerate an infarcted heart. However, 
mouse models do not always mimic human heart phenotypes (Ma et al., 2013). One 
ideal tool for disease-modeling could be the use of single cardiomyocytes isolated from 
patients, although they are rarely available and cannot be kept in culture for a long time 
nor can they be expanded in vitro.  
 The potential of regenerative medicine has grown considerably since the Nobel 
Prize laureate Yamanaka reported that genetic reprogramming by ectopic expression of 
transcription factor genes (Oct4, Sox2, Klf4, c-Myc) induces the pluripotent state in 
somatic cells, which then become ‘induced pluripotent stem cells’ (iPSCs) (Takahashi 
et al., 2007). iPSCs have major advantages including self-renewal and their capacity to 
differentiate into patient-specific cell lineages (Galera et al., 2016; Zurita et al., 2016). 
Nonetheless, iPSCs-derived cardiomyocytes feature immature, fetal-like 
cardiomyocytes rather than adult cells. They have a round shape, sarcomeric structures 
with different degrees of organization (Figure 1A), limited calcium handling ability, or 
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spontaneous contractions. In contrast, mature cardiomyocytes are larger, rod-shaped, 
they are often multinucleated and have more organized sarcomeres as well as a more 
negative resting potential. Thus,  iPSCs-based disease modeling is overall more suitable 
for early-onset cardiac diseases. There is thus an urgent need for new and robust 
experimental systems allowing the modeling of heart diseases irrespective of the age of 
onset. Several approaches have been used to convert iPSCs-derived cardiomyocytes into 
cells with more mature phenotypes such as long-term culture, electric stimulation, 
increased substrate stiffness, the use of special scaffolds and the Matrigel mattress 
method (Feaster et al., 2015; Mummery et al., 2003), although more in depth research is 
still needed. Lee and coworkers recently showed that co-culturing ESC-derived 
cardiomyocytes with endothelial cells improved the maturation stage of cardiomyocytes 
(Lee et al., 2015). By comparing microRNAs (miRNA) expression profiles in 
cardiomyocytes derived from ESC co-cultured with endothelial cells versus ESC 
cultured alone, these authors identified a combination of 4 miRNAs (miR-125b, miR-
199a, mir-221, miR-222) that were differentially up-regulated only in the former. 
Further, transfection of this miRNA combination mimicked the aforementioned 
‘maturation’ effect in the cardiomyocytes that were derived from ESC cultured alone. 
Interestingly, a previous study had demonstrated that miR-222 modulates 
cardiomyocyte growth while conferring protection against adverse myocardial 
remodeling (Liu et al., 2015). 
 Current medical options for protecting the heart against pathological remodeling, 
notably after AMI, are sparse. Although there is not yet an ‘ideal’ perfect cellular model 
allowing to fully imitating the adult cardiomyocyte phenotype, pioneering results might 
set a starting point towards the development of a robust experimental methodology 
allowing generation of mature human- or iPSCs-derived cardiomyocytes for assessing 
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cardiac regeneration therapies (see Figure 1B for a summary). Finally, several 
emerging therapy options such as transplantation of iPSCs-derived cardiomyocytes, in 
vivo reprogramming of cardiac fibroblasts in the scar region to induce cardiomyocytes, 
generation of engineered heart muscle, or even reactivating the telomerase gene, 
represent the new horizon in cardiology with an appropriate 180-degree turn 
perspective. 
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Figure Legend 
Figure 1.  
A) Human cardiomyocytes generated from induced pluripotential stem cells (iPSCs) in 
our laboratory: these cells show varying degrees of organization within the same 
preparation, i.e., a more immature phenotype (left photograph) versus a more 
differentiated phenotype with more organized, adult-like sarcomeres (right photograph). 
Structural characterization of cardiomyocytes obtained from iPSCs by modulating 
Wnt/β-catenin signalling (Lian et al., 2013). iPSCs were first generated from NHDF 
control fibroblasts, acquired in Promocell, using a Sendai virus-based reprogramming 
methodology (Cytotune 2.0, Life Technologies). Immunostaining for α-actinin (in pink) 
and cardiac troponin T (cTnT) (in green) shows sarcomere organization. Nuclei were 
stained with DAPI (in blue).  
B) Generation of patient-specific cardiomyocytes for cardiovascular disease therapy. 
Cardiomyocytes can be generated in vitro using (i) iPSC reprogramming and 
subsequent differentiation or (ii) direct reprogramming (‘trans-differentiation’) into 
induced cardiomyocytes (Zhu et al., 2015). Disease-specific mutations within iPSCs can 
be previously corrected by genomic edition approaches such as the CRISPR/Cas9 
system. In both cases, cardiomyocytes must undergo additional maturation before they 
can serve as models of adult cardiomyocytes. Direct in vivo reprogramming therapy to 
regenerate damaged cardiac tissue is also indicated as a future therapy. 
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Figure 1.  
A) Human cardiomyocytes generated from induced pluripotential stem cells (iPSCs) in our laboratory: these 
cells show varying degrees of organization within the same preparation, i.e., a more immature phenotype 
(left photograph) versus a more differentiated phenotype with more organized, adult-like sarcomeres (right 
photograph). Structural characterization of cardiomyocytes obtained from iPSCs by modulating Wnt/β-
catenin signalling (Lian et al., 2013). iPSCs were first generated from NHDF control fibroblasts, acquired in 
Promocell, using a Sendai virus-based reprogramming methodology (Cytotune 2.0, Life Technologies). 
Immunostaining for α-actinin (in pink) and cardiac troponin T (cTnT) (in green) shows sarcomere 
organization. Nuclei were stained with DAPI (in blue).  
B) Generation of patient-specific cardiomyocytes for cardiovascular disease therapy. Cardiomyocytes can be 
generated in vitro using (i) iPSC reprogramming and subsequent differentiation or (ii) direct reprogramming 
(‘trans-differentiation’) into induced cardiomyocytes (Zhu et al., 2015). Disease-specific mutations within 
iPSCs can be previously corrected by genomic edition approaches such as the CRISPR/Cas9 system. In both 
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cases, cardiomyocytes must undergo additional maturation before they can serve as models of adult 
cardiomyocytes. Direct in vivo reprogramming therapy to regenerate damaged cardiac tissue is also 
indicated as a future therapy.  
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